ATLANTA--(BUSINESS WIRE)--Jun. 10, 2009-- Underscoring its strong industry position to help healthcare organizations achieve “meaningful use,” Eclipsys Corporation® (NASDAQ: ECLP), The Outcomes Company®, today announced that KLAS has reported that the company leads the industry in the number of physicians using its computerized physician order entry (CPOE) system in acute care hospitals and the percentage of its client base deeply using CPOE. The company also has the highest physician satisfaction from clients using its Sunrise Acute Care™ solution.

The recently enacted American Recovery and Reinvestment Act of 2009 (ARRA) offers federal incentives to hospitals and providers for achieving “meaningful use of an electronic health record (EHR).” ARRA also has stirred debate as to whether a specific EHR technology can deliver the level of clinician adoption required to surpass the required threshold of “meaningful use.”

According to the recently issued KLAS “Meaningful Use Leading to Improved Outcomes” report, deep adoption is pivotal to the overarching success of an electronic medical record (EMR) implementation. The KLAS report noted Eclipsys is among the vendors that are by far the most successful with regard to physician adoption, and that survey respondents cited the company as able to provide an integrated ambulatory EMR solution to the marketplace that is well-positioned to meet the meaningful use criteria.

In addition, KLAS concluded that Eclipsys has an advantage in both physician satisfaction and time required to order with the company’s CPOE system. After surveying Eclipsys CPOE clients, KLAS also reported that:

• When looking at deep CPOE adoption, Eclipsys ranks highest among vendors, with 41 percent of its 200+ bed client base actually entering more than 50 percent of all orders electronically with CPOE.
• Eclipsys is strong in getting new clients live quickly with CPOE, proving that a focused and quick approach works.
• 24 percent of all CPOE-using physicians in acute care hospitals utilize Eclipsys.
• Eclipsys has the second highest number of non-employed physicians doing CPOE with its system.

“We are pleased this new KLAS report brings to light that our company dominates the market performance for physician satisfaction with CPOE in acute care hospitals and points out our advantage to meet forthcoming ARRA requirements,” said Jay Deady, Eclipsys executive vice president of Client Solutions. “We’re also pleased that the findings highlight the fundamental distinction providers should make in considering EMR vendors for ARRA, which is not the number of hospital sites a vendor may have, but within those sites, how many doctors are actually doing CPOE?”

Eclipsys’ CPOE high adoption rates and speed are a factor of its embedded complex algorithms that transcend fundamental order entry to automatically interpret and recalculate new order protocols in real time based on any updates to the patient condition. With more than 30 years of experience, Eclipsys has leveraged the input of thousands of physicians for evidence-based order sets and frequently used protocols to achieve unmatched, continuous evolution in its CPOE capabilities. Built on the Sunrise Enterprise™ XA extended architecture™, the intuitive, easy-to-adopt solution offers highly complex clinical decision support capabilities that provide workflows tailored to how physicians practice medicine and support fully automating even the most complex order sets and medication ordering, including the exacting protocols, long-range medication schedules and complicated treatment plans commonplace in oncology and pediatric care environments.

About the Meaningful Use Leading to Improved Outcomes report

The Meaningful Use Leading to Improved Outcomes report compiled data from healthcare executives, managers and clinicians. The study provided detailed information of core clinical vendors on several criteria including current CPOE usage at healthcare organizations, product capabilities, vendor performance ratings, and other components that are considered germane to the concept of meaningful use.

About KLAS

KLAS is a research firm specializing in monitoring and reporting the performance of healthcare vendors. KLAS' mission is to improve delivery, by independently measuring vendor performance for the benefit of our healthcare provider partners, consultants, investors, and vendors. Working together with executives from over 4500 hospitals and over 2500 clinics, KLAS delivers timely reports, trends, and statistics, which provide a solid overview of vendor performance in the industry. KLAS measures performance of software, professional services, and medical equipment vendors. For more information, go to www.KLASresearch.com, or email marketing@KLASresearch.com, or call 1-800-920-4109 to speak with a KLAS representative.

About Eclipsys

Eclipsys is a leading provider of advanced integrated clinical, revenue cycle and performance management software, clinical content and professional services that help healthcare organizations improve clinical, financial and operational outcomes. For more information, see www.eclipsys.com or email info@eclipsys.com.

Statements in this news release concerning the timing of implementation and features and benefits provided by Eclipsys software, evidence-based content and implementation and remote hosting services are forward-looking statements and actual results may differ from those projected due to a variety of risks and uncertainties. Implementation and customization of Eclipsys software is complex and time-consuming. Results depend upon a variety of factors and can vary by client. Each client’s circumstances are unique and may include unforeseen issues that make it more difficult than anticipated to implement or derive benefit from Eclipsys software or services. The success and timeliness of the company’s services will depend at least in part upon client involvement, which can be difficult to control. Eclipsys is required to meet specified performance standards, and the contract can be terminated or its scope reduced under certain circumstances. More information about company risks is available in recent Form 10-Q and 10-K filings made by Eclipsys from time to time with the Securities and Exchange Commission. Special attention is directed to the portions of those documents entitled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations.” Eclipsys Corporation and The Outcomes Company are registered trademarks of Eclipsys Corporation. Sunrise Acute Care, Sunrise Enterprise and XA extended architecture are trademarks of Eclipsys Corporation. Other product and company names in this news release are or may be trademarks and/or registered trademarks of their respective companies.

Source: Eclipsys

Eclipsys:
Robin Wrinn, 404-847-5219
Public Relations
(media)
robin.wrinn@eclipsys.com
or
Jason Cigarran, 404-847-5965
Vice President, Investor Relations
jason.cigarran@eclipsys.com